Fanconi anemia pathway as a prospective target for cancer intervention

Cell & Bioscience

Table 1 A summary of reported FA proteininhibitors and available structures or biochemical activities to facilitate drug development

FA genes	Protein structures	Molecular activities	Inhibitors	References
FANCA	6LHS	DNA binding, strand annealing and exchange	HSP90i including withaferin A	[66, 81, 128, 132]
FANCF	2IQC		Natural compounds from Wrightia religiosa	[133, 134]
FANCL	3ZQS, 4CCG	E3 ligase	CU1, CU2	[34, 131, 135]
FANCM	4BXO, 4DAY, 4DRB, 4E45, 4M6W	DNA binding	MM2 peptide	[136,137,138,139,140,141]
FANCT/UBE2T	1YH2, 4CCG, 5NGZ, 5OJJ	E2	A few leads by fragment screening	[34, 142,143,144]
FANCD2	3S4W	DNA binding		[145]
FANCI	3S51	DNA binding	Undisclosed	[146, 147]
FANCP/SLX4	4M7C, 4UYI, 4ZOU	DNA binding		[148]
FANCD1/BRCA2	1N0W, 3EU7	DNA binding	Antisense oligonucleotide (ASO)	[149,150,151]
FANCJ/BRIP1	1T15, 1T29, 3AL3	Helicase		[152,153,154]
FANCN/PALB2	2W18, 3EU7	DNA binding		[150]
FANCO/RAD51C		DNA binding
FANCR/RAD51	1B22, 1N0W, 5H1B, 5H1C, 5JZC, 5NP7, 5NWL	Strand exchange	RI-1, RI-2, B02, CYT01A	[149, 155,156,157,158,159,160,161]
FANCS/BRCA1	1JM7, 1JNX, 1N5O, 1OQA, 1T15, 1T29, 1T2U, 1T2V, 1Y98, 2ING, 3COJ, 3K0H, 3K0K, 3K15, 3K16, 3PXA, 3PXB, 3PXC, 3PXD, 3PXE, 4IFI, 4IGK, 4JLU, 4OFB, 4U4A, 4Y18, 4Y2G, 6G2I	DNA binding		[152, 153, 162,163,164,165,166,167,168,169,170,171,172,173,174]
FANCV/REV7	3ABD, 3ABE, 3VU7, 4EXT, 4GK0, 4GK5, 5XPT, 5XPU, 6BC8, 6BCD, 6BI7	DNA binding	REV7 specific compounds	[175,176,177,178,179,180]
FANCW/RFWD3	6CVZ	E3
FANCQ/XPF	1Z00, 2A1J, 2AQ0, 2KN7, 2MUT	DNA incision		[181,182,183,184,185]

ISSN: 2045-3701